Please login to the form below

Not currently logged in
Email:
Password:

Still's disease

This page shows the latest Still's disease news and features for those working in and with pharma, biotech and healthcare.

Novartis’ canakinumab failed to improve survival in COVID-19 study

Novartis’ canakinumab failed to improve survival in COVID-19 study

Canakinumab, which Novartis already sells under the brand name Ilaris, is a once-monthly biologic used to treat systemic juvenile idiopathic arthritis and active Still’s disease. ... year. “There’s still an urgent need for effective ways to combat

Latest news

  • Maintenance OK boosts AstraZeneca’s Lynparza in Europe Maintenance OK boosts AstraZeneca’s Lynparza in Europe

    to-treat disease.”. ... AZ and Merck’s drug is still in front in terms of sales, bringing in $218m last year, compared to $109m for Zejula and $55m for Rubraca.

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia

  • Another Alzheimer's bust as Merck & Co stops verubecestat study Another Alzheimer's bust as Merck & Co stops verubecestat study

    Merck Research Laboratories president Roger Perlmutter said the company is "disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer's disease.".

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... around 2, 500 people in

  • Lilly closes Avid buy

    Lilly has made major investments in the Alzheimer's disease space, with several key treatments still in development in spite of the recent failure of its late-stage product candidate semagacestat. . ... other diseases, including Parkinson's disease and

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics